Evidence map›Paper›PMID 42201730›Full record

ArticleJAMA surgery2026

Glycemic Control and Diabetes Outcomes After Surgical Therapy for Diabetic Gastroparesis.

Vineeth R Sadda, Rhea Verma, Ahmed E Aly, Ping Zheng, Shahin Ayazi

Abstract readMulticenter Study
In one paragraph

Article in JAMA surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vineeth R SaddaForegut Division, Surgical Institute, Allegheny Health Network, Pittsburgh, Pennsylvania.
Rhea VermaForegut Division, Surgical Institute, Allegheny Health Network, Pittsburgh, Pennsylvania.
Ahmed E AlyForegut Division, Surgical Institute, Allegheny Health Network, Pittsburgh, Pennsylvania.
Ping ZhengForegut Division, Surgical Institute, Allegheny Health Network, Pittsburgh, Pennsylvania.
Shahin AyaziForegut Division, Surgical Institute, Allegheny Health Network, Pittsburgh, Pennsylvania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Surgical therapy for gastroparesis is effective for refractory symptoms; however, its association with glycemic control and diabetes-related complications in patients with diabetic gastroparesis remains uncertain. Objective: To evaluate the association between surgical therapy for gastroparesis and glycemic control and diabetes-related complications in adults with diabetic gastroparesis. Design, Setting, and Participants: This retrospective multicenter cohort study using a national electronic health record database included more than 100 million patients from more than 70 US health care organizations. Adults with concurrent diagnoses of diabetes and gastroparesis between 2010 and 2023 were included. Propensity score matching (1:1) was performed. Queries and analyses were performed in January and February 2026. Exposure: Surgical therapy for gastroparesis, including gastric electrical stimulation, pyloroplasty, and gastric peroral endoscopic myotomy. Main Outcomes and Measures: The primary outcome was mean glycated hemoglobin (HbA1c) level over follow-up. Secondary outcomes included probability of adequate glycemic control (HbA1c <7%), severe hyperglycemia (HbA1c ≥10%), insulin utilization, diabetes-related complications, health care utilization, and mortality. Results: A total of 95 328 eligible patients were identified, including 2272 (2.4%) who underwent surgical therapy. The mean (SD) age was 54.9 (15.2) years; 61 245 (64.2%) were female and 34 083 (35.6%) male. After propensity score matching, 2272 patients remained in each cohort. The mean (SD) follow-up time was 3.5 (1.7) years. Baseline HbA1c was similar between groups. Over follow-up, mean HbA1c decreased by 0.51 percentage points in the surgical cohort and increased by 0.28 percentage points in the nonoperative cohort. At 5 years, mean (SD) HbA1c was 6.29% (1.72) in the surgical group and 7.21% (2.02) in the nonoperative group (between-group difference, 0.92 percentage points; P < .001). The surgical cohort had a higher probability of achieving adequate glycemic control, lower probability of severe hyperglycemia, and lower initiation of insulin therapy. At 5 years, diabetes-related complications occurred in 1209 surgical patients (53.2%) and 1438 nonoperative patients (63.3%; odds ratio, 1.52; 95% CI, 1.34-1.71; P < .001). Emergency visits (947 [41.7%] vs 1243 [54.7%]) and hospitalizations (1034 [45.5%] vs 1340 [59.0%]) were also less frequent (both P < .001). Five-year mortality did not differ (232 [10.4%] vs 232 [10.4%]; P > .99). Conclusions and Relevance: In this national multicenter cohort, surgical therapy was associated with improved glycemic control, lower insulin utilization, and fewer diabetes-related complications. Metabolic outcomes may warrant consideration alongside symptom relief when evaluating patients for surgical therapy for gastroparesis.

Indexed as

Diabetes ComplicationsGastroparesisGlycemic ControlAdultFemaleGlycated HemoglobinHumansMaleMiddle AgedPropensity ScorePyloromyotomyRetrospective StudiesTreatment OutcomeGlycated Hemoglobin

Identifiers

PMID42201730
PMCPMC13217260

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.